Home › Liver Cancer (Hepatocellular Carcinoma) › NCT06342414

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* A histologically confirmed diagnosis of hepatocellular carcinoma
* A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma
* Received standard diagnostic and staging procedures as per local guidelines
* Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment

Exclusion Criteria:

* Lack of or inability to provide informed consent
* Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
* Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma
* Secondary liver cancer

About the study

It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.

What is being tested

• ELUCIDATE (diagnostic test)

Sponsor: City of Hope Medical Center · Participants: 400 · Started: Mar 15, 2024

Contact the study team

• Ajay Goel, PhD · Phone: 6262183452

Official record on ClinicalTrials.gov — NCT06342414

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)
• Bile Duct Cancer (Cholangiocarcinoma)
• Liver Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.